Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.
The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.
Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase III Study Assessing Early versus Delayed Treatment with Venetoclax and Obinutuzumab for Newly Diagnosed Patients with High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma without Symptoms
Efrat Luttwak
[Protocol 21-117]
Prior Treatment (Relapsed/Refractory)
A Phase 2 Study of Venetoclax, Obinutuzumab, and Acalabrutinib to Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Andrew D. Zelenetz
[Protocol 22-359]
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers
Lorenzo Falchi
[Protocol 25-152]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 2 Study of Glofitamab-based Treatment in Older People With Diffuse Large B-cell Lymphoma
Pallawi Torka
[Protocol 24-332]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
A Phase 2 Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Pallawi Torka
[Protocol 25-070]
A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers
Lorenzo Falchi
[Protocol 25-152]
A Phase 1-2 Study of Englumafusp Alfa Plus Glofitamab in People With B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 25-250]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Mosunetuzumab as Initial Chemotherapy-Free Treatment for Follicular Lymphoma
Lorenzo Falchi
[Protocol 22-100]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers
Lorenzo Falchi
[Protocol 25-152]
A Phase 2 Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Pallawi Torka
[Protocol 25-070]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Study of Daratumumab plus EPOCH Chemotherapy to Treat Plasmablastic Lymphoma
Ariela Noy
[Protocol 20-033]
Prior Treatment (Relapsed/Refractory)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Raphael Steiner
[Protocol 23-381]
A Phase 2 Study of BV-AVD in People With Newly Diagnosed Bulky Hodgkin Lymphoma
Robert Stuver
[Protocol 24-039]
A Phase 3 Study of Brentuximab Vedotin in People With Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 24-116]
Prior Treatment (Relapsed/Refractory)
A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 18-160]
A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Raphael Steiner
[Protocol 23-381]
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Pilot Study of Glofitamab and Lenalidomide in People With Previously Treated Mantle Cell Lymphoma
Anita Kumar
[Protocol 23-319]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers
Lorenzo Falchi
[Protocol 25-152]
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]
A Phase III Study Assessing Early versus Delayed Treatment with Venetoclax and Obinutuzumab for Newly Diagnosed Patients with High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma without Symptoms
Efrat Luttwak
[Protocol 21-117]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers
Lorenzo Falchi
[Protocol 25-152]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alison J. Moskowitz
[Protocol 21-343]
A Phase 2 Study of Brentuximab Vedotin With Chemotherapy in People With T-Cell Lymphoma
Robert Stuver
[Protocol 24-139]
Prior Treatment (Relapsed/Refractory)
A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
Steven M. Horwitz
[Protocol 21-140]
A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas
Alison J. Moskowitz
[Protocol 21-176]
A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma
William Johnson
[Protocol 22-045]
A Phase 2 Study of Enasidenib in People With T-Cell Lymphoma
Zachary Epstein-Peterson
[Protocol 23-269]
A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia
Alison J. Moskowitz
[Protocol 23-280]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Alison J. Moskowitz
[Protocol 16-1542]
A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Alison J. Moskowitz
[Protocol 18-147]
A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas
Alison J. Moskowitz
[Protocol 21-176]
A Phase II Study of Pembrolizumab Immunotherapy plus Gemcitabine to Treat Advanced Mycosis Fungoides or Sézary Syndrome
Alison J. Moskowitz
[Protocol 21-242]
A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma
William Johnson
[Protocol 22-045]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 1/2 Study of STP938 in People With B-Cell or T-Cell Lymphoma
Robert Stuver
[Protocol 24-219]
A Phase 1 Study of Alectinib Plus Duvelisib in People With ALK-Positive Anaplastic Large Cell Lymphoma
Robert Stuver
[Protocol 25-056]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 2 Study of Brentuximab Vedotin With Chemotherapy in People With T-Cell Lymphoma
Robert Stuver
[Protocol 24-139]
Prior Treatment (Relapsed/Refractory)
A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
Steven M. Horwitz
[Protocol 21-140]
A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas
Alison J. Moskowitz
[Protocol 21-176]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study Assessing Venetoclax Added to Ibrutinib and Rituximab for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
M. Lia Palomba
[Protocol 21-336]
A Phase 2 Study of BGB-11417 in People With Waldenström's Macroglobulinemia
M. Lia Palomba
[Protocol 24-067]
A Phase 2 Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
M. Lia Palomba
[Protocol 25-149]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 23-077]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 2 Study of BGB-11417 in People With Waldenström's Macroglobulinemia
M. Lia Palomba
[Protocol 24-067]
A Phase 1 Study of ARV-393 for People With Non-Hodgkin's Lymphoma
Andrew D. Zelenetz
[Protocol 24-362]
We’re available 24 hours a day, 7 days a week
